{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:12:21Z","timestamp":1771942341636,"version":"3.50.1"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rescue therapies for relapsed\/refractory (r\/r) metastatic neoplasias present significant unmet needs. Tumor tissue editing regimen for 13 r\/r tumor types, carcinomas, sarcomas and hematologic neoplasias, included in 15 phase I\/II trials, nuclear\/cytokine receptor agonists, pioglitazone, plus\/minus dexamethasone or all-trans retinoic acid or interferon-\u03b1 to counterbalance tumor tissue homeostasis and reprogramming of cancer hallmarks, stress response inhibitors, COX-2 inhibitor, everolimus, lenalidomide, or clarithromycin, and a stress response inducer, low-dose metronomic chemotherapy with treosulfan, trofosfamide, capecitabine, or azacitidine. CR in three, cCR in another five r\/r neoplasias, as the best response occurred after transcriptional reprogramming of cancer hallmarks, inflammation control or differentiation induction. Receptor agonist combinations for cCR induction can be identical among quite different tumor types and diversified within the same tumor histology. Data reveal ubiquitous, differential transcriptional access to non-oncogene addiction (NOA) networks that cope with cancer hallmarks\/stress responses and three levels of therapeutic NOA targeting. (1) Agonists of nuclear\/cytokine receptor NOAs critically target tumor identity and viability, while (2) transcriptional reprogramming of NOA networks that contribute to tumor tissue addiction, thereby genome-agnostically counteracting oncogene addictions. (3) Targeting edited NOAs may improve long-term outcome with CR\/cCR (everolimus, IMiD). Transcriptionally accessible NOA targets offer high specificity, modest toxicity profile, low cost of therapy and outpatient treatment, independent of comorbidities. Adaptive targeting of the transcriptomic landscapes of tumor cell compartments breaks tumor tissue addiction and overcomes M-CRAC, post-therapy metastasis, cancer cell recolonization, acquired resistance and genetic heterogeneity. Thus, editing approaches provide a template for controlling metastatic r\/r tumors. In the future, diagnostics of NOA networks and transcription factors involved in tumor tissue addiction may be as valuable for therapy selection as histological\/molecular genetic tumor typing for the establishment of personalized hematology\/oncology.<\/jats:p>","DOI":"10.3389\/fphar.2026.1629187","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:41:12Z","timestamp":1771940472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed\/refractory neoplasias"],"prefix":"10.3389","volume":"17","author":[{"given":"Dennis Christoph","family":"Harrer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"L\u00fcke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg","place":["Regensburg, Germany"]},{"name":"Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Pukrop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg","place":["Regensburg, Germany"]},{"name":"Bavarian Cancer Research Center (BZKF), University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ghibelli","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Heudobler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg","place":["Regensburg, Germany"]},{"name":"Bavarian Cancer Research Center (BZKF), University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD013798","DOI":"10.1002\/14651858.CD013798.pub2","article-title":"First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"5","author":"Aldin","year":"2023","journal-title":"Cochrane Database Sys. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.bjc.6603271","article-title":"Interleukin-2\/interferon-alpha2a\/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"95","author":"Atzpodien","year":"2006","journal-title":"Br. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","article-title":"Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment","volume":"54","author":"Barkley","year":"2022","journal-title":"Nat. Genetics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.cels.2020.08.018","article-title":"The stress-like cancer cell state is a consistent component of tumorigenesis","volume":"11","author":"Baron","year":"2020","journal-title":"Cell Systems"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cells13171506","article-title":"Class effect unveiled: PPAR\u03b3 agonists and MEK inhibitors in cancer cell differentiation","volume":"13","author":"Ben-Yishay","year":"2024","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1016\/j.cell.2022.11.021","article-title":"Spatial proteomics in three-dimensional intact specimens","volume":"185","author":"Bhatia","year":"2022","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102674","DOI":"10.1016\/j.ctrv.2023.102674","article-title":"Histology independent drug development - is this the future for cancer drugs?","volume":"123","author":"Billingham","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1038\/s41388-022-02496-3","article-title":"Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain","volume":"41","author":"Blazquez","year":"2022","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer - from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/msb.2010.117","article-title":"Rewiring makes the difference","volume":"7","author":"Califano","year":"2011","journal-title":"Mol. Sys. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa067208","article-title":"Aspirin and the risk of colorectal cancer in relation to the expression of COX-2","volume":"356","author":"Chan","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1084\/jem.20151665","article-title":"Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells","volume":"213","author":"Chan","year":"2016","journal-title":"J. Exp. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/biom11020129","article-title":"Targeting non-oncogene addiction for cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Biomolecules"},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","article-title":"The role and regulation of integrins in cell migration and invasion","volume":"26","author":"Chastney","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial landscapes of cancers: insights and opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","article-title":"How cancer cells make and respond to interferon-I","volume":"9","author":"Cheon","year":"2023","journal-title":"Trends Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/genes15020197","article-title":"NF-\u03baB: governing macrophages in cancer","volume":"15","author":"Cornice","year":"2024","journal-title":"Genes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/ijms23031152","article-title":"Apoptosis as driver of therapy-induced cancer repopulation and acquired cell-resistance (CRAC): a simple in vitro model of phoenix rising in prostate cancer","volume":"23","author":"Corsi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"116254","DOI":"10.1016\/j.bcp.2024.116254","article-title":"Non-oncogene dependencies: novel opportunities for cancer therapy","volume":"228","author":"Di Marco","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bbcan.2013.11.003","article-title":"Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-\u03b3 (PPAR-\u03b3): at the cross-road of pancreatic cancer cell proliferation","volume":"1845","author":"Dicitore","year":"2014","journal-title":"Biochimica Biophysica Acta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13105-021-00791-3","article-title":"Downregulation of fatty acid oxidation by involvement of HIF-1\u03b1 and PPAR\u03b3 in human gastric adenocarcinoma and related clinical significance","volume":"77","author":"Ezzeddini","year":"2021","journal-title":"J. Physiol. Biochem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1158\/1078-0432.CCR-03-0382","article-title":"Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs","volume":"10","author":"Gehrmann","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nri1748","article-title":"Combinatorial roles of nuclear receptors in inflammation and immunity","volume":"6","author":"Glass","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00280-010-1294-0","article-title":"Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids","volume":"67","author":"Gottfried","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2174\/092986712799320727","article-title":"mTOR as a target of everolimus in refractory\/relapsed Hodgkin lymphoma","volume":"19","author":"Guarini","year":"2012","journal-title":"Curr. Medicinal Chemistry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1432-1033.1986.tb09655.x","article-title":"Differential human interferon alpha receptor expression on proliferating and non-proliferating cells","volume":"157","author":"Hannigan","year":"1986","journal-title":"Eur. J. Biochem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1080\/10428194.2022.2095627","article-title":"Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis","volume":"63","author":"Harrer","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1289222","DOI":"10.3389\/fonc.2023.1289222","article-title":"Peroxisome proliferator-activated receptor\u03b1\/\u03b3 agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity","volume":"13","author":"Harrer","year":"","journal-title":"Front. Oncology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/cancers16010180","article-title":"Addressing genetic tumor heterogeneity, post-therapy metastatic spread, cancer repopulation, and development of acquired tumor cell resistance","volume":"16","author":"Harrer","year":"","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1553331","DOI":"10.3389\/fphar.2025.1553331","article-title":"MEPED as salvage therapy for relapsed\/refractory Hodgkin\u2019s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck","volume":"16","author":"Harrer","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12307-015-0170-1","article-title":"Anakoinosis: communicative reprogramming of tumor systems - for rescuing from chemorefractory Neoplasia","volume":"8","author":"Hart","year":"2015","journal-title":"Cancer Microenviron. J. Int. Cancer Microenviron. Soc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/jdv.13391","article-title":"Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial","volume":"30","author":"Hart","year":"2016","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"595835","DOI":"10.3389\/fimmu.2020.595835","article-title":"C-reactive protein and cancer-diagnostic and therapeutic insights","volume":"11","author":"Hart","year":"2020","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000120028","article-title":"Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study","volume":"73","author":"Hau","year":"2007","journal-title":"Oncology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41586-024-08280-5","article-title":"\u03c0-HuB: the proteomic navigator of the human body","volume":"636","author":"He","year":"","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12964-023-01438-0","article-title":"Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to immunotherapy","volume":"22","author":"He","year":"","journal-title":"Cell Commun. Signal."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","article-title":"The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma","volume":"81","author":"Heider","year":"2021","journal-title":"Mol. Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc2108","article-title":"Reprogramming metastatic tumour cells with embryonic microenvironments","volume":"7","author":"Hendrix","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"624112","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fphar.2018.01279","article-title":"Cutaneous leukemic infiltrates successfully treated with biomodulatory therapy in a rare case of therapy-related high risk MDS\/AML","volume":"9","author":"Heudobler","year":"","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3389\/fphar.2018.01357","article-title":"Clinical efficacy of a novel therapeutic principle, anakoinosis","volume":"9","author":"Heudobler","year":"","journal-title":"Front. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.1200\/JCO.2019.37.15_suppl.8037","article-title":"Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed\/refractory multiple myeloma > second-line","volume":"37","author":"Heudobler","year":"","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3389\/fonc.2019.01408","article-title":"Anakoinosis: correcting aberrant homeostasis of cancer tissue-going beyond apoptosis induction","volume":"9","author":"Heudobler","year":"","journal-title":"Front. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"599598","DOI":"10.3389\/fphar.2021.599598","article-title":"A randomized phase II trial comparing the efficacy and safety of pioglitazone, Clarithromycin and metronomic low-dose chemotherapy with single-agent nivolumab therapy in patients with advanced non-small cell lung cancer treated in second or further line (ModuLung)","volume":"12","author":"Heudobler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3324\/haematol.2023.283864","article-title":"Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged \u226560 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16\/AML-ViVA): results of the safety run-in phase","volume":"109","author":"Heudobler","year":"","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1385766","DOI":"10.3389\/fonc.2024.1385766","article-title":"Editorial: integrating transcriptional modulation in systemic tumor therapy","volume":"14","author":"Heudobler","year":"","journal-title":"Front. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41540-019-0104-5","article-title":"Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types","volume":"5","author":"Hjaltelin","year":"2019","journal-title":"NPJ Sys. Biol. Appl."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat. Commun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-19-1242","article-title":"Targeting cancer cell metastasis by converting cancer cells into fat","volume":"79","author":"Ishay-Ronen","year":"2019","journal-title":"Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1523-1755.2005.00666.x","article-title":"Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue","volume":"68","author":"Jabs","year":"2005","journal-title":"Kidney Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.21873\/cgp.20504","article-title":"DEFA1, primarily expressed at the invasive tumor front, promotes OSCC cell invasion and tumor growth","volume":"22","author":"Jeong","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"key":"B62","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41577-024-01003-x","article-title":"Bone marrow inflammation in haematological malignancies","volume":"24","author":"Jong","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2012","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fonc.2020.00443","article-title":"Successful treatment of early relapsed high-risk AML after allogeneic hematopoietic stem cell transplantation with biomodulatory therapy","volume":"10","author":"Kattner","year":"2020","journal-title":"Front. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ol.2024.14839","article-title":"Transcription factors and hormone receptors: sex-specific targets for cancer therapy","volume":"29","author":"Kim","year":"2025","journal-title":"Oncol. Letters"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fphar.2018.01380","article-title":"Biomodulatory treatment with azacitidine, all-trans retinoic acid and pioglitazone induces differentiation of primary AML blasts into neutrophil like cells capable of ROS production and phagocytosis","volume":"9","author":"Klobuch","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"10431","DOI":"10.3390\/ijms221910431","article-title":"PPAR\u03b3 and TGF\u03b2-major regulators of metabolism, inflammation, and fibrosis in the lungs and kidneys","volume":"22","author":"K\u00f6k\u00e9ny","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"189054","DOI":"10.1016\/j.bbcan.2023.189054","article-title":"Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma","volume":"1879","author":"Kusaczuk","year":"2024","journal-title":"Biochimica Biophysica Acta. Rev. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.cell.2023.07.014","article-title":"Pan-cancer proteogenomics connects oncogenic drivers to functional states","volume":"186","author":"Li","year":"2023","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","article-title":"LSD1-Mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression","volume":"77","author":"Liang","year":"2017","journal-title":"Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/a:1023366117157","article-title":"PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro","volume":"79","author":"Liu","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"B72","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-019-0635-8","article-title":"Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes","volume":"7","author":"Lu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"599561","DOI":"10.3389\/fphar.2021.599561","article-title":"Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin\u2019s disease","volume":"12","author":"L\u00fcke","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"900985","DOI":"10.3389\/fonc.2022.900985","article-title":"Drug repurposing by tumor tissue editing","volume":"12","author":"L\u00fcke","year":"2022","journal-title":"Front. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41577-023-00949-8","article-title":"The cancer-immune dialogue in the context of stress","volume":"24","author":"Ma","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00109-016-1401-8","article-title":"Therapy-induced microenvironmental changes in cancer","volume":"94","author":"Ma","year":"2016","journal-title":"J. Mol. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/cancers17030441","article-title":"Heterogeneity in cancer","volume":"17","author":"MacDonald","year":"2025","journal-title":"Cancers"},{"key":"B80","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199708143370703","article-title":"Origin of nodular lymphocyte-predominant Hodgkin\u2019s disease from a clonal expansion of highly mutated germinal-center B cells","volume":"337","author":"Marafioti","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1534735406291499","article-title":"Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy","volume":"5","author":"McCarty","year":"2006","journal-title":"Integr. Cancer Therapies"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.3390\/cancers16162862","article-title":"Advances in personalized oncology","volume":"16","author":"Mechahougui","year":"2024","journal-title":"Cancers"},{"key":"B83","doi-asserted-by":"publisher","first-page":"826346","DOI":"10.3389\/fchem.2022.826346","article-title":"A proteomic platform enables to test for AML normalization in vitro","volume":"10","author":"Meier-Menches","year":"2022","journal-title":"Front. Chemistry"},{"key":"B84","doi-asserted-by":"publisher","first-page":"C749","DOI":"10.1152\/ajpcell.00537.2006","article-title":"Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells","volume":"293","author":"Meng","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"848645","DOI":"10.1155\/2010\/848645","article-title":"Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma","volume":"2009","author":"Meyer","year":"2009","journal-title":"PPAR Res."},{"key":"B86","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-90-481-9531-2_22","article-title":"Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant Melanoma","volume-title":"Albrecht reichle (Hg.): from molecular to modular tumor therapy","author":"Meyer","year":"2010"},{"key":"B87","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1568009619666191209102015","article-title":"PPAR\u03b3 agonists in combination cancer therapies","volume":"20","author":"Mrowka","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"B88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1074\/mcp.M116.063313","article-title":"Multi-omics analysis of serum samples demonstrates reprogramming of organ functions via systemic calcium mobilization and platelet activation in metastatic Melanoma","volume":"16","author":"Muqaku","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.15252\/embr.201643030","article-title":"Drugging the addict: non-oncogene addiction as a target for cancer therapy","volume":"17","author":"Nagel","year":"2016","journal-title":"EMBO Rep."},{"key":"B90","first-page":"4190","article-title":"Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein","volume":"50","author":"Nanus","year":"1990","journal-title":"Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.3390\/cancers13236062","article-title":"Therapeutic influence on important targets associated with chronic inflammation and oxidative stress in cancer treatment","volume":"13","author":"Neganova","year":"2021","journal-title":"Cancers"},{"key":"B92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","article-title":"Network pharmacology: curing causal mechanisms instead of treating symptoms","volume":"43","author":"Nogales","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fphar.2019.00287","article-title":"A computational model of tumor growth and anakoinosis","volume":"10","author":"Pantziarka","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/jcp.24601","article-title":"PPAR\u03b3 and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche","volume":"229","author":"Papi","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","article-title":"Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment","volume":"21","author":"Petroni","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B96","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1038\/s41467-024-50678-2","article-title":"Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer","volume":"15","author":"Plumber","year":"2024","journal-title":"Nat. Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.urolonc.2009.11.012","article-title":"C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results","volume":"30","author":"Prins","year":"2012","journal-title":"Urol. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood.2023023789","article-title":"The current landscape of frontline large B-cell lymphoma trials","volume":"145","author":"Qualls","year":"2025","journal-title":"Blood"},{"key":"B100","article-title":"Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology","volume-title":"Naunyn-Schmiedeberg's archives of pharmacology","author":"Ranjan","year":"2024"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-481-9531-2","volume-title":"From molecular to modular tumor therapy","author":"Reichle","year":"2010"},{"key":"B102","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-007-6866-6_13","article-title":"Modularity, subjectivity, intersubjectivity and normativity: clinically applicable operative benchmarks","volume-title":"Albrecht reichle (Hg.): Evolution-adjusted tumor pathophysiology","author":"Reichle","year":"2013"},{"key":"B103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12307-009-0023-x","article-title":"Principles of modular tumor therapy","volume":"2","author":"Reichle","year":"2009","journal-title":"Cancer Microenviron. J. Int. Cancer Microenviron. Soc."},{"key":"B104","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12307-008-0012-5","article-title":"Systems biology: a therapeutic target for tumor therapy","volume":"1","author":"Reichle","year":"2008","journal-title":"Cancer Microenviron. J. Int. Cancer Microenviron. Soc."},{"key":"B105","first-page":"87","article-title":"C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation","volume":"1","author":"Reichle","year":"","journal-title":"Biomark. Insights"},{"key":"B106","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/CMR.0b013e3282f1d2c8","article-title":"Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial","volume":"17","author":"Reichle","year":"","journal-title":"Melanoma Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e15584","DOI":"10.1200\/jco.2009.27.15_suppl.e15584","article-title":"Control of cancer-associated inflammation and survival: results from a prospective randomized phase II trial in gastric cancer","volume":"27","author":"Reichle","year":"2009","journal-title":"J Clin. Oncol"},{"key":"B108","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-90-481-9531-2_16","article-title":"Pioglitazone and rofecoxib combined with angiostatically scheduled capecitabine in far-advanced hepatobiliary carcinoma","volume-title":"Albrecht reichle (Hg.): from molecular to modular tumor therapy","author":"Reichle","year":"2010"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1334233","DOI":"10.3389\/fphar.2024.1334233","article-title":"Case report: sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin\u2019s disease developing resistance to pembrolizumab","volume":"15","author":"Reuthner","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood.2019000934","article-title":"Langerhans cell histiocytosis","volume":"135","author":"Rodriguez-Galindo","year":"2020","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12885-024-11985-5","article-title":"PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil","volume":"24","author":"Sch\u00f6ckel","year":"2024","journal-title":"BMC Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.bbamcr.2006.09.006","article-title":"Peroxisomes and oxidative stress","volume":"1763","author":"Schrader","year":"2006","journal-title":"Biochimica Biophysica Acta"},{"key":"B114","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s10875-011-9530-x","article-title":"Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining","volume":"31","author":"Schwandt","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.trecan.2016.06.004","article-title":"Adaptive stress responses during tumor metastasis and dormancy","volume":"2","author":"Senft","year":"2016","journal-title":"Trends Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"115229","DOI":"10.1016\/j.celrep.2024.115229","article-title":"The spatial landscape of cancer hallmarks reveals patterns of tumor ecology","volume":"44","author":"Sibai","year":"2022","journal-title":"Cell Rep."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e1388485","DOI":"10.1080\/2162402X.2017.1388485","article-title":"Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition","volume":"7","author":"Siddiqui","year":"2018","journal-title":"Oncoimmunology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41586-023-06017-4","article-title":"A druggable copper-signalling pathway that drives inflammation","volume":"617","author":"Solier","year":"2023","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.cell.2007.09.007","article-title":"Non-oncogene addiction and the stress phenotype of cancer cells","volume":"130","author":"Solimini","year":"2007","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3390\/cancers15061866","article-title":"Non-oncogene addiction of KRAS-mutant cancers to IL-1\u03b2 via versican and mononuclear IKK\u03b2","volume":"15","author":"Spella","year":"2023","journal-title":"Cancers"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-0716-2815-7_9","article-title":"Targeting transcription factors in cancer: from \u201cUndruggable\u201d to \u201cDruggable\u201d","volume":"2594","author":"Tao","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"932632","DOI":"10.1155\/2008\/932632","article-title":"PPARgamma, PTEN, and the fight against cancer","volume":"2008","author":"Teresi","year":"2008","journal-title":"PPAR Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cell.2024.11.002","article-title":"Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing","volume":"188","author":"Tetzlaff","year":"2025","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/cancers16142529","article-title":"Target-driven tissue-agnostic drug approvals-A new path of drug development","volume":"16","author":"Thein","year":"2024","journal-title":"Cancers"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.3324\/haematol.2014.115055","article-title":"Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia","volume":"100","author":"Thomas","year":"2015","journal-title":"Haematologica"},{"key":"B127","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V85.2.433.433","article-title":"Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans","volume":"85","author":"Tilg","year":"1995","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/jir.2014.0106","article-title":"Interferon alpha and metronomic cyclophosphamide for metastatic kidney cancer: a phase 2 study","volume":"35","author":"Tupikowski","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bjh.13480","article-title":"Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma","volume":"172","author":"Ugocsai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2018.00745","article-title":"Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT\/\u03b2-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis","volume":"9","author":"Vall\u00e9e","year":"2018","journal-title":"Front. Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/2326-6066.CIR-16-0110","article-title":"Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups","volume":"4","author":"Velasco","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e12863","DOI":"10.1111\/sji.12863","article-title":"Interferon \u03b1 in cancer immunoediting: from elimination to escape","volume":"91","author":"Vidal","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pharmthera.2019.04.004","article-title":"Stress responses in stromal cells and tumor homeostasis","volume":"200","author":"Vitale","year":"2019","journal-title":"Pharmacol. Therapeutics"},{"key":"B135","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12307-014-0161-7","article-title":"Biomodulatory treatment of patients with castration-resistant prostate cancer: a phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan","volume":"8","author":"Vogelhuber","year":"2015","journal-title":"Cancer Microenviron."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.11775","article-title":"Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors","volume":"98","author":"Vogt","year":"2003","journal-title":"Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(06)70798-7","article-title":"Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes","volume":"7","author":"Vogt","year":"2006","journal-title":"Lancet. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/bloodadvances.2024015285","article-title":"Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma","volume":"9","author":"Waldschmidt","year":"2025","journal-title":"Blood Adv."},{"key":"B140","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00345-010-0567-x","article-title":"Modular therapy approach in metastatic castration-refractory prostate cancer","volume":"28","author":"Walter","year":"2010","journal-title":"World J. Urol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12032-017-1040-0","article-title":"Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial","volume":"34","author":"Walter","year":"2017","journal-title":"Med. Oncol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"13804","DOI":"10.3390\/ijms241813804","article-title":"Roles of stress response in autophagy processes and aging-related diseases","volume":"24","author":"Watanabe","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes--the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res."},{"key":"B145","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s44164-022-00040-x","article-title":"3D spheroid culture to examine adaptive therapy response in invading tumor cells","volume":"1","author":"Weiss","year":"2022","journal-title":"Vitro Models"},{"key":"B146","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41388-024-02953-1","article-title":"YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression","volume":"43","author":"Xiao","year":"2024","journal-title":"Oncogene"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"key":"B148","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1631\/jzus.B2300492","article-title":"\u514d\u75ab\u68c0\u67e5\u70b9\u963b\u65ad\u7684\u764c\u75c7\u6cbb\u7597:\u6700\u65b0\u8fdb\u5c55\u4e0e\u5c55\u671b","volume":"26","author":"Ye","year":"2025","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"B149","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11523-024-01095-4","article-title":"Real-life experience with entrectinib in neurotrophic tyrosine receptor kinase fusion-positive solid tumors: a multicenter retrospective trial","volume":"19","author":"Y\u0131lmaz","year":"2024","journal-title":"Target. Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2651790","DOI":"10.1155\/2022\/2651790","article-title":"The effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-pharmtox-010611-134520","article-title":"Systems pharmacology: network analysis to identify multiscale mechanisms of drug action","volume":"52","author":"Zhao","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2217\/fon.12.202","article-title":"Oncogene and non-oncogene addiction in inflammation-associated cancers","volume":"9","author":"Zheng","year":"2013","journal-title":"Future Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1629187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:41:15Z","timestamp":1771940475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1629187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":155,"alternative-id":["10.3389\/fphar.2026.1629187"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1629187","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1629187"}}